Quick Answer
Silexion Therapeutics Corp reported Research And Development Expense of $7.14 million for the year ending 2025.
- Silexion Therapeutics Corp showed an increase of +22.8% in Research And Development Expense from 2024 to 2025.
- This data is from Silexion Therapeutics Corp's annual report (Form 10-K), filed with the SEC on March 17, 2026.
- XBRL data for this metric is available from 2023 to 2025 (3 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q2 2023: $1.24 million | Q3 2023: $535.0 thousand | Q1 2024: $961.0 thousand | Q2 2024: $766.0 thousand | Q3 2024: $3.22 million | Q1 2025: $590.0 thousand | Q2 2025: $1.02 million | Q3 2025: $2.16 million.
- Over the full 3 years of available data (2023 to 2025), Silexion Therapeutics Corp's Research And Development Expense has grown by 92.6%.
- Historical annual values: Fiscal year 2025: $7.14 million | Fiscal year 2024: $5.82 million | Fiscal year 2023: $3.71 million.
- Data sourced from SEC EDGAR public filings as of August 10, 2026.
Last verified: